Three Abstracts on the ChemoFx(R) Drug Response Marker Accepted by ASCO - MarketWatch
".....The third abstract titled, In Vitro Chemoresponse Assay Results and Population Clinical Response Rates in Women with Ovarian Cancer, determines whether in vitro platinum sensitivity rates are similar to published population response rates for ovarian cancer and examines differences in platinum sensitivity across histologic subtypes."
"We are very pleased with the outcomes to date from these three
studies," says Dr. Karl Williams, Chief Medical Director for Precision
Therapeutics, Inc. "We look forward to watching these projects progress
and further analyzing the value of ChemoFx for these difficult to treat
patients."
For more information, visit:
www.precisiontherapeutics.com
or
www.chemofx.com .
SOURCE: Precision Therapeutics Inc.
